Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Incyte Corporation (INCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 24,929,996
  • Shares Outstanding, K 205,710
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 104,220 K
  • 36-Month Beta 0.85
  • Price/Sales 22.65
  • Price/Cash Flow 130.24
  • Price/Book 24.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
121.00 +0.16%
on 08/18/17
139.59 -13.18%
on 07/27/17
-9.66 (-7.38%)
since 07/18/17
3-Month
115.20 +5.20%
on 06/12/17
139.98 -13.42%
on 05/25/17
-7.61 (-5.91%)
since 05/18/17
52-Week
75.52 +60.47%
on 08/19/16
153.15 -20.87%
on 03/15/17
+45.03 (+59.13%)
since 08/18/16

Most Recent Stories

More News
Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma

If you want a Stock Review on IMGN, INCY, INFI, or JAZZ then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com is currently focused...

JAZZ : 144.40 (-1.10%)
IMGN : 6.01 (-0.99%)
INCY : 121.19 (-0.45%)
INFI : 1.00 (-8.26%)
Forbes Magazine Names Incyte One of the World's Most Innovative Companies for Third Consecutive Year

Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th on Forbes magazine's 2017 list of the World's Most Innovative Companies. Incyte, a biopharmaceutical company focused...

INCY : 121.19 (-0.45%)
After Yesterday's Rally of 2.10% Shares Could Potentially Pullback

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $128.24 to a high of $133.11. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of...

INCY : 121.19 (-0.45%)
Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong

Incyte (INCY) reported a wider-than-expected loss in the second quarter but revenues beat expectations.

MRK : 61.49 (-0.57%)
INCY : 121.19 (-0.45%)
NVS : 82.76 (-0.50%)
BMY : 56.42 (-0.62%)
Today's Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and Incyte Corporation

NEW YORK, NY / ACCESSWIRE / August 2, 2017 / AcelRx Pharmaceuticals saw a big drop in Tuesday trading after announcing second quarter results that failed to meet expectations. The company did, however,...

ACRX : 2.95 (-1.67%)
INCY : 121.19 (-0.45%)
Incyte Corp Falls 4.10% on Heavy Volume: Watch For Potential Rebound

Incyte Corp (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $127.57 to a high of $134.94. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $131.82...

INCY : 121.19 (-0.45%)
Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs

--Proof-of-concept data for the combination of epacadostat plus PD-1 inhibition presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2017 across multiple tumor types; expanded Phase...

INCY : 121.19 (-0.45%)
Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY

The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.

AERI : 53.05 (-3.19%)
JNJ : 132.63 (-0.31%)
MRK : 61.49 (-0.57%)
LLY : 77.07 (-0.94%)
INCY : 121.19 (-0.45%)
NVS : 82.76 (-0.50%)
ABBV : 69.96 (+0.16%)
PFE : 32.67 (-0.85%)
BIIB : 281.77 (-0.93%)
Key Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline

Why were Lilly's (LLY) shares down despite the company delivering a "beat and raise" quarter?

MRK : 61.49 (-0.57%)
LLY : 77.07 (-0.94%)
INCY : 121.19 (-0.45%)
PFE : 32.67 (-0.85%)
Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

IRWD : 14.50 (unch)
MDCO : 35.50 (+0.28%)
INCY : 121.19 (-0.45%)
GILD : 72.11 (-0.32%)
AMGN : 167.29 (-0.31%)
BIIB : 281.77 (-0.93%)
NKTR : 18.04 (-2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of...

See More

Support & Resistance

2nd Resistance Point 123.01
1st Resistance Point 122.10
Last Price 121.19
1st Support Level 120.64
2nd Support Level 120.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.